| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | -9,407 | -19,567 |
| Proceeds from exercise of options | 28 | 3 |
| Net cash provided by financing activities | 28 | 3 |
| Net change in cash and cash equivalents | -41,335 | -40,686 |
| Cash and cash equivalents at beginning of period | 51,470 | - |
| Cash and cash equivalents at end of period | 10,135 | - |
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)